^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Guanylate cyclase stimulant

    Related drugs:
    7d
    SPY NITROPASTE: Enhancing Wound Perfusion in High-Risk Lower Extremity Orthopaedic Surgery: A Study on Nitropaste Using Intraoperative SPY Imaging. (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Johns Hopkins University | Initiation date: Mar 2026 --> Nov 2026 | Trial primary completion date: Mar 2027 --> Sep 2027
    Trial initiation date • Trial primary completion date
    |
    nitroglycerin
    19d
    Understanding relationships between skin microvascular and limb macrovascular structure and function assessed by optical coherence tomography and high-resolution ultrasound in response to physiological stimuli (flow-mediated dilation, local heating, carbon dioxide and glyceryl trinitrate) in healthy younger and older adults. (ACTRN12626000357358)
    P=N/A, N=80, Not yet recruiting, The University of Western Australia
    New trial
    |
    nitroglycerin
    20d
    Glyceryl Trinitrate Gel Phonophoresis on Planter Fasciiatis (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Cairo University
    New trial
    |
    nitroglycerin
    21d
    Protective Effects of Riociguat Against Contrast-Induced Nephropathy: An Experimental and Machine Learning-Based Study in Rats. (PubMed, Kaohsiung J Med Sci)
    The apoptotic index and nitric oxide were identified as dominant predictors, indicating mechanistic relevance but limited clinical screening utility because these predictors require histological assessment. Overall, riociguat demonstrated significant renoprotective effects through anti-apoptotic, anti-inflammatory, and antioxidative mechanisms, and machine learning provided hypothesis-generating insight rather than a clinically deployable predictive model.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • LCN2 (Lipocalin-2)
    1m
    iNO300 Therapy in Critically Ill Patients With Pneumonia (clinicaltrials.gov)
    P1, N=34, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    Alleviation of nitroglycerin-induced migraine in rats: inhibition of central sensitization by optimizing Qinggan Jieyu decoction regulation of purinergic receptor P2X ligand-gated ion channel 7 and autophagy. (PubMed, J Tradit Chin Med)
    QGJY alleviates migraine and inhibits central sensitization in rats, potentially by downregulating P2X7R expression, concomitantly suppressing autophagy, attenuating microglial activation, and reducing pro-inflammatory cytokine release.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • VEGFD (Vascular Endothelial Growth Factor D) • IL1B (Interleukin 1, beta) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
    |
    nitroglycerin
    2ms
    Unanticipated intraoperative haemodynamic challenges during adrenalectomy for a phaeochromocytoma misdiagnosed as an adrenocortical tumour. (PubMed, BMJ Case Rep)
    Intraoperatively, tumour manipulation precipitated abrupt hypertensive surges with bradycardia, necessitating nitroglycerine and sodium nitroprusside infusion. Intraoperative haemodynamic instability during adrenal manipulation should raise suspicion of catecholamine secretion, even in the absence of classical symptoms. The report emphasises the importance of invasive monitoring and anaesthetic preparedness to manage unexpected catecholamine release.
    Journal
    |
    SYP (Synaptophysin)
    |
    nitroglycerin
    2ms
    Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty (clinicaltrials.gov)
    P2, N=10, Completed, University of Colorado, Denver | Recruiting --> Completed | N=20 --> 10 | Trial completion date: Dec 2024 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    2ms
    Spatial metabolomics combined with MALDI-MSI unveils gut-brain axis mechanisms of angelica dahurica radix in migraine rats. (PubMed, Phytomedicine)
    Baizhi alleviates migraine through multi-target regulation of the gut-brain axis, including intestinal barrier repair, gut microbiota remodeling, and cerebral metabolic restoration. Notably, this study on Baizhi represents the first integration of spatial metabolomics (MALDI-MSI) with gut microbiome and systemic metabolomics to elucidate migraine mechanisms, providing a novel multi-omics strategy for understanding the holistic therapeutic effects of traditional Chinese medicine. These findings provide a mechanistic basis for its clinical application in migraine treatment.
    Preclinical • Journal • Metabolomic study
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TJP1 (Tight Junction Protein 1) • OCLN (Occludin)
    |
    nitroglycerin
    2ms
    Effect of discontinuation of riociguat on right heart function in patients with chronic thromboembolic pulmonary hypertension after combination therapy (ChiCTR2500099401)
    P=N/A, N=68, Not yet recruiting, Beijing Chao-Yang Hospital, Capital Medical University; Beijing Chao-Yang Hospital, Capital Medical University | Phase classification: P4 --> P=N/A
    Phase classification
    2ms
    A prospective, randomized, controlled clinical study on the treatment of patients with decompensated chronic heart failure and diuretic resistance with recombinant human brain natriuretic peptide (ChiCTR2500114713)
    P=N/A, N=100, Not yet recruiting, Tianjin Chest Hospital; Tianjin Chest Hospital
    New trial
    2ms
    Study on the efficacy and safety of recombinant human brain natriuretic peptide (Xinhuosu) in the treatment of acute heart failure patients (randomized controlled trial) Study on the efficacy and safety of recombinant human brain natriuretic peptide (Xinhuosu) in the treatment of acute heart failure patients (randomized controlled trial) (ChiCTR2500112523)
    P=N/A, N=514, Not yet recruiting, Fuwai Hospital, Chinese Academy of Medical Sciences; Fuwai Hospital, Chinese Academy of Medical Sciences
    New trial